Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Neurovirol. 2019 Jun 4;25(6):735–740. doi: 10.1007/s13365-019-00759-6

TABLE 1.

Demographic characteristics of participants. (CES-D=Center for Epidemiologic Studies Depression Scale)

By CD4 Count

HIV+ (n=399) < 200 (n=200) 350–500 (n=199) p

Male [n (%)] 212 (53%) 121 (60%) 91 (46%) 0.003
Age (years) [mean (SD)] 35 (8) 34 (7) 37 (9) 0.001
CD4 count [mean (SD)] ---- 95 (61) 420 (43) ----
Education (years) [mean (SD)] 5 (3) 5 (4) 5 (3) 0.39
Body Mass Index (BMI) [mean (SD)] 21.8 (3.5) 20.6 (2.8) 23.0 (3.7) < 0.001
 Underweight [n (%)] 51 (13%) 44 (22%) 7 (4%) < 0.001
 Overweight/obese [n (&)] 53 (13%) 7 (4%) 46 (23%) < 0.001
CES-D Score [mean (SD)] 10 (9) 12 (10) 8 (9) 0.001
 Depression (CES-D >= 16) [n (%)] 96 (24%) 61 (30%) 35 (18%) 0.002
Diabetes [n (%)] 0 (0%) ---- ---- -----
Hypertension [n (%)] 4 (1%) 0 (0%) 4 (2%) 0.04
Tobacco use [n (%)] 63 (16%) 39 (20%) 24 (12%) 0.04
Narcotics use [n (%)] 12 (3%) 10 (5%) 2 (1%) 0.02
Alcohol use in past month [n (%)] 195 (49%) 90 (45%) 105 (52%) 0.13
HAND [n (%)] 236 (59%) 131 (66%) 105 (53%) 0.01
Peripheral neuropathy [n (%)] 76 (19%) 36 (18%) 40 (20%) 0.59
Headaches [n (%)]* 55 (42%) 4 (40%) 51 (42%) 1.0
Mortality [n (%)]+ 17 (5%) 14 (8%) 3 (2%) 0.005
*

Headaches were surveyed in a subgroup of 130 participants (n=10 with CD4<200 cells/μL and n=120 with CD4 350–500 cells/μL). Remaining participants were excluded from this analysis.

+

Vital status was ascertained in 354 participants (n=166 with CD4<200 cells/μL and n=188 with CD4 350–500 cells/μL). Participants lost to follow-up (n=45) were excluded from this analysis.